AU2004279837B2 - A method for the treatment of malignant diseases by inhibiting nucleolin - Google Patents

A method for the treatment of malignant diseases by inhibiting nucleolin Download PDF

Info

Publication number
AU2004279837B2
AU2004279837B2 AU2004279837A AU2004279837A AU2004279837B2 AU 2004279837 B2 AU2004279837 B2 AU 2004279837B2 AU 2004279837 A AU2004279837 A AU 2004279837A AU 2004279837 A AU2004279837 A AU 2004279837A AU 2004279837 B2 AU2004279837 B2 AU 2004279837B2
Authority
AU
Australia
Prior art keywords
nucleolin
cells
antibody
cell
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004279837A
Other languages
English (en)
Other versions
AU2004279837A1 (en
Inventor
Paula J. Bates
Donald M. Miller
John O. Trent
Xiaohua Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Publication of AU2004279837A1 publication Critical patent/AU2004279837A1/en
Application granted granted Critical
Publication of AU2004279837B2 publication Critical patent/AU2004279837B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
AU2004279837A 2003-10-09 2004-10-08 A method for the treatment of malignant diseases by inhibiting nucleolin Ceased AU2004279837B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/683,480 2003-10-09
US10/683,480 US7357928B2 (en) 2002-04-08 2003-10-09 Method for the diagnosis and prognosis of malignant diseases
PCT/US2004/033174 WO2005035579A1 (en) 2003-10-09 2004-10-08 A method for the treatment of maligant diseases by inhibiting nucleolin

Publications (2)

Publication Number Publication Date
AU2004279837A1 AU2004279837A1 (en) 2005-04-21
AU2004279837B2 true AU2004279837B2 (en) 2010-04-01

Family

ID=34435395

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004279837A Ceased AU2004279837B2 (en) 2003-10-09 2004-10-08 A method for the treatment of malignant diseases by inhibiting nucleolin

Country Status (7)

Country Link
US (4) US7357928B2 (enExample)
EP (1) EP1687337B1 (enExample)
JP (1) JP2008502584A (enExample)
AU (1) AU2004279837B2 (enExample)
CA (1) CA2546730C (enExample)
ES (1) ES2473598T3 (enExample)
WO (1) WO2005035579A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2296615T3 (es) * 1999-04-08 2008-05-01 Antisoma Research Limited Actividad antiproliferativa de oligonucleotidos ricos en g y procedimiento de uso de los mismos para su union a la nucleolina.
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20110178161A1 (en) * 1999-04-08 2011-07-21 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
CA2489520A1 (en) * 2002-06-26 2004-01-08 University Of Louisville Research Foundation, Inc. A method for the detection of apoptosis
US7831293B2 (en) * 2005-05-10 2010-11-09 Advanced Clinical Solutions, Inc. Method of defining a biological target for treatment
CN102539734B (zh) * 2005-05-12 2016-02-03 清华大学 核仁素辅助的癌症诊断与治疗方法
FR2900341B1 (fr) 2006-04-27 2012-09-14 Centre Nat Rech Scient Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
US8481529B2 (en) 2006-05-16 2013-07-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combination cancer chemotherapy
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009023184A2 (en) 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
ATE487487T1 (de) * 2007-09-04 2010-11-15 Inst Nat Sante Rech Med Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
WO2009088837A2 (en) * 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
WO2009098464A2 (en) * 2008-02-05 2009-08-13 Antisoma Research Limited Biological materials and uses thereof
WO2009141687A1 (en) 2008-05-22 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) New optically pure compounds for improved therapeutic efficiency
CN102223896A (zh) * 2008-08-07 2011-10-19 西塞医疗中心 抗-β-2-微球蛋白试剂及其用途
KR100998365B1 (ko) * 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
US8737715B2 (en) * 2009-07-13 2014-05-27 H. Lee Moffitt Cancer And Research Institute, Inc. Methods and apparatus for diagnosis and/or prognosis of cancer
CN108707584A (zh) * 2009-11-17 2018-10-26 Musc研究发展基金会 针对人核仁素的人单克隆抗体
CA2790342C (en) * 2010-02-19 2019-10-01 The Ohio State University Primers and methods for nucleic acid amplification
US10030045B2 (en) * 2010-02-19 2018-07-24 Ohio State Innovation Foundation Primers and methods for nucleic acid amplification
WO2011109677A2 (en) * 2010-03-04 2011-09-09 University Of Louisville Research Foundation, Inc. Methods of increasing macropinocytosis in cancer cells
WO2012045751A2 (en) 2010-10-04 2012-04-12 Centre National De La Recherche Scientifique (Cnrs) Multivalent synthetic compounds as antibiotic treatment
PL3446714T3 (pl) 2011-06-02 2021-11-22 University Of Louisville Research Foundation, Inc. Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie
WO2013067268A1 (en) * 2011-11-03 2013-05-10 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
WO2014187856A1 (en) * 2013-05-21 2014-11-27 Deutsches Krebsforschungszentrum Nucleoli disorganisation by knocking down specific alu-repeat containing rna sequences
EP3291839A1 (en) 2015-05-05 2018-03-14 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
CN106405096A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备胃癌诊断试剂和治疗药物中的应用
CN106405084A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备肠癌诊断试剂和治疗药物中的应用
US11357849B2 (en) 2016-03-07 2022-06-14 Musc Foundation For Research Development Anti-nucleolin antibodies
US20170338925A1 (en) * 2016-05-20 2017-11-23 National Taiwan University Scheduling method of communication system using directional reference signals and related apparatuses using the same
AU2017277647B2 (en) 2016-06-08 2023-07-27 President And Fellows Of Harvard College Engineered viral vector reduces induction of inflammatory and immune responses
WO2018026958A1 (en) 2016-08-02 2018-02-08 The University Of Louisville Research Foundation, Inc. Targeted nanodroplet emulsions for treating cancer
WO2018175309A1 (en) * 2017-03-20 2018-09-27 Cancer Therapeutics Laboratories, Inc. Tumor necrosis targeting compositions and methods
KR20200085812A (ko) 2017-11-08 2020-07-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 바이러스 벡터-유도된 염증 반응을 억제하기 위한 조성물 및 방법
CA3153487A1 (en) 2019-09-10 2021-03-18 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-peg-conjugated nanoparticles
JP7692419B2 (ja) * 2019-12-24 2025-06-13 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
WO2021202425A1 (en) 2020-03-28 2021-10-07 University Of Louisville Research Foundation, Inc. Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent
WO2021225423A1 (ko) * 2020-05-07 2021-11-11 인터올리고 주식회사 신규 핵산 리간드 및 그의 식별방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07242566A (ja) * 1994-03-01 1995-09-19 Kirin Brewery Co Ltd 免疫抑制剤
WO2001032832A2 (en) * 1999-11-03 2001-05-10 Isis Pharmaceuticals, Inc. Antisense inhibition of nucleolin expression
DE10037861A1 (de) * 2000-08-01 2002-02-14 Max Delbrueck Centrum Mittel zur Therapie maligner Erkrankungen
AU2003228431A1 (en) * 2002-04-05 2003-10-27 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4474892A (en) * 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4665897A (en) * 1984-05-25 1987-05-19 Lemelson Jerome H Composition and method for detecting and treating cancer
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5192660A (en) * 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
AU635008B2 (en) * 1989-12-13 1993-03-11 Genelabs Diagnostics Pte Ltd Analytical apparatus and method for automated blot assay
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5736348A (en) * 1990-11-28 1998-04-07 Fundacao Oswaldo Cruz (Fiocruz) Method for the immunological diagnosis of Chagas' Disease using recombinant antigens
JPH05244988A (ja) 1992-03-04 1993-09-24 Green Cross Corp:The 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
US6096532A (en) * 1995-06-07 2000-08-01 Aastrom Biosciences, Inc. Processor apparatus for use in a system for maintaining and growing biological cells
ES2279531T3 (es) 1995-12-15 2007-08-16 Intronn, Inc. Moleculas terapeuticas generadas por corte y empalme en trans.
US6048703A (en) * 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
WO1998040480A1 (en) 1997-03-12 1998-09-17 Institut Pasteur A novel cell surface receptor for hiv retroviruses, therapeutic and diagnostic uses
WO1998055615A1 (en) * 1997-06-05 1998-12-10 The University Of Texas Board Or Regents Apaf-1, the ced-4 human homolog, an activator of caspase-3
CA2293632C (en) * 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6339075B1 (en) * 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
WO1999006588A1 (en) 1997-08-04 1999-02-11 The Burnham Institute A cell-free system of mitochondria-dependent apoptosis, and methods of use thereof
US6325785B1 (en) * 1997-08-14 2001-12-04 Sherwood Services Ag Sputum trap manifold with nested caps
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US5932475A (en) * 1997-12-12 1999-08-03 Incyte Pharmaceuticals, Inc. Human nucleolin-like protein
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU762572B2 (en) 1998-04-10 2003-06-26 Chugai Seiyaku Kabushiki Kaisha Protein and gene involved in myocyte differentiation
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
AU6162999A (en) * 1998-09-24 2000-04-10 Promega Corporation Apoptosis marker antibodies and methods of use
ES2296615T3 (es) 1999-04-08 2008-05-01 Antisoma Research Limited Actividad antiproliferativa de oligonucleotidos ricos en g y procedimiento de uso de los mismos para su union a la nucleolina.
CA2363984A1 (en) 1999-04-15 2000-10-26 Merck Frosst Canada & Co. Antibodies that recognize app cleaved by caspases and methods of use
US7070924B1 (en) 1999-11-08 2006-07-04 Eisai Co., Ltd. Method of detecting cell death and detection reagent
JP2001213804A (ja) 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd 抗組織因子抗体の複合体
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
CA2404890C (en) 2000-03-30 2013-11-19 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
WO2001091771A2 (en) 2000-06-01 2001-12-06 Theralife, Inc. Compositions for treating back and leg discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins
CA2410903A1 (en) 2000-06-02 2001-12-06 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US7129084B2 (en) 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
CA2454277C (en) 2001-07-16 2006-09-12 Arla Foods Amba Process for manufacturing of tagatose
WO2003029277A2 (en) 2001-10-03 2003-04-10 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
CA2489520A1 (en) 2002-06-26 2004-01-08 University Of Louisville Research Foundation, Inc. A method for the detection of apoptosis
TW200504210A (en) 2003-07-30 2005-02-01 Chin-Tarng Lin A nucleolin antisense inhibiting growth of cancer cell
WO2005037323A2 (en) 2003-10-10 2005-04-28 University Of Louisville Research Foundation, Inc. Use of gro to treat or prevent inflammation
CN102539734B (zh) 2005-05-12 2016-02-03 清华大学 核仁素辅助的癌症诊断与治疗方法
WO2007016466A2 (en) 2005-07-29 2007-02-08 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses therefor
WO2009088837A2 (en) 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
EP2437653B1 (en) 2009-10-21 2014-07-23 Health Research, INC. Paa nanoparticles for enhancement of tumor imaging
US20110111002A1 (en) 2009-11-12 2011-05-12 Calin Viorel Pop Transport and delivery of glutathione into human cells using gold nanoparticles
CN108707584A (zh) 2009-11-17 2018-10-26 Musc研究发展基金会 针对人核仁素的人单克隆抗体
WO2011119058A2 (en) 2010-03-22 2011-09-29 Universidade De Coimbra F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases
PL3446714T3 (pl) 2011-06-02 2021-11-22 University Of Louisville Research Foundation, Inc. Nanocząstki sprzężone z cząsteczką skierowaną przeciwko nukleolinie
JP5244988B1 (ja) 2012-02-20 2013-07-24 浜松ホトニクス株式会社 濃度測定装置および濃度測定方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07242566A (ja) * 1994-03-01 1995-09-19 Kirin Brewery Co Ltd 免疫抑制剤
WO2001032832A2 (en) * 1999-11-03 2001-05-10 Isis Pharmaceuticals, Inc. Antisense inhibition of nucleolin expression
DE10037861A1 (de) * 2000-08-01 2002-02-14 Max Delbrueck Centrum Mittel zur Therapie maligner Erkrankungen
AU2003228431A1 (en) * 2002-04-05 2003-10-27 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Grinstein, E. et al., J Exp Med, Vol.196, No.8, 2002, pages 1067-1078 *
Yingchang, M. et al. Proc Am Assoc Cancer Res. Vol.43, 2002, Abstract 4752 *

Also Published As

Publication number Publication date
CA2546730A1 (en) 2005-04-21
CA2546730C (en) 2017-03-21
WO2005035579A1 (en) 2005-04-21
US7357928B2 (en) 2008-04-15
US20050053607A1 (en) 2005-03-10
US20120014942A1 (en) 2012-01-19
ES2473598T3 (es) 2014-07-07
EP1687337B1 (en) 2014-03-26
AU2004279837A1 (en) 2005-04-21
US20090017009A1 (en) 2009-01-15
US8029784B2 (en) 2011-10-04
US20140220013A1 (en) 2014-08-07
US8586717B2 (en) 2013-11-19
JP2008502584A (ja) 2008-01-31
EP1687337A1 (en) 2006-08-09

Similar Documents

Publication Publication Date Title
AU2004279837B2 (en) A method for the treatment of malignant diseases by inhibiting nucleolin
US7541150B2 (en) Method for the diagnosis and prognosis of malignant diseases
US20110065121A1 (en) Method for the detection of apoptosis
US20210322513A1 (en) Method for detecting cancer cells, reagent for introducing substance into cancer cells, and composition for treating cancer
US20230310607A1 (en) Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
JP2024056774A (ja) アネキシンａ１を介した心血管石灰化の阻害に関する方法および組成物
WO2014061419A1 (ja) 新規癌マーカーおよびその利用
KR101741898B1 (ko) Claudin 7을 포함하는 방사선 반응성 위암 진단용 바이오마커 조성물
EP1862178A1 (en) Use of HLTF antibodies for diagnosis and treatment of cancer
CN101583621A (zh) 治疗、诊断或检测癌症的amigo-2抑制剂
Connolly Generation and characterisation of antibodies specific for the multidrug resistance-associated protein, MRP

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS TO AMEND THE INVENTION TITLE TO READ: A METHOD FOR THE TREATMENT OF MALIGNANT DISEASES BY INHIBITING NUCLEOLIN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired